5-甲氧基-3-甲基苯并呋喃-2-羧酸 | 81718-77-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并呋喃
• 中文名称: 5-甲氧基-3-甲基苯并呋喃-2-羧酸
• 英文名称: 5-methoxy-3-methyl-benzofuran-2-carboxylic acid
• 英文别名: 5-Methoxy-3-methyl-benzofuran-2-carbonsaeure；5-methoxy-3-methyl-1-benzofuran-2-carboxylic acid
• CAS: 81718-77-6
• 化学式: C₁₁H₁₀O₄
• mdl: MFCD03964697
• 分子量: 206.198
• InChiKey: BKOHXOOAJNTFCM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.181
• 拓扑面积：
  59.7
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2932999099

反应信息

• 作为反应物：
  描述：

  5-甲氧基-3-甲基苯并呋喃-2-羧酸 、 重氮甲烷 生成 methyl 5-methoxy-3-methylbenzofuran-2-carboxylate
  参考文献：
  名称：

  SUZUKI, TSUNEO;HORAGUCHI, TAKAAKI;SHIMIZU, TAKAHACHI;ABE, TEISHIRO, BULL. CHEM. SOC. JAP., 1983, 56, N 9, 2762-2767

  摘要：

  DOI：
• 作为产物：
  描述：

  3-溴-6-甲氧基-4-甲基-2H-色烯-2-酮 在 氢氧化钾 作用下， 生成 5-甲氧基-3-甲基苯并呋喃-2-羧酸
  参考文献：
  名称：

  Dalvi; Sethna, Journal of the Indian Chemical Society, 1949, vol. 26, p. 467,469

  摘要：

  DOI：

文献信息

• Protease inhibitors
  申请人：SmithKline Beecham Corporation

  公开号：US20030144175A1

  公开（公告）日：2003-07-31

  The present invention provides 4-amino-azepan-3-one protease inhibitors and pharmaceutically acceptable salts, hydrates and solvates thereof which inhibit proteases, including cathepsin K, pharmaceutical compositions of such compounds, novel intermediates of such compounds, and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis; gingival disease including gingivitis and periodontitis; arthritis, more specifically, osteoarthritis and rheumatoid arthritis; Paget's disease; hypercalcemia of malignancy; and metabolic bone disease, comprising inhibiting said bone loss or excessive cartilage or matrix degradation by administering to a patient in need thereof a compound of the present invention.

  本发明提供了4-氨基-氮杂七环-3-酮蛋白酶抑制剂及其药用可接受的盐、水合物和溶剂化物，其抑制蛋白酶，包括卡特普辛K，这些化合物的药物组合物，这些化合物的新中间体，以及治疗骨骼过度流失或软骨或基质降解疾病的方法，包括骨质疏松症；牙龈疾病，包括牙龈炎和牙周炎；关节炎，更具体地说，是骨关节炎和类风湿关节炎；帕吉特病；恶性高钙血症；和代谢性骨病，包括通过向需要的患者施用本发明化合物来抑制骨质流失或过度软骨或基质降解。
• Benzofuran Derivatives. I. On the Effects of Substituents in Benzofuran Syntheses
  作者：Tsuneo Suzuki、Takaaki Horaguchi、Takahachi Shimizu、Teishiro Abe

  DOI：10.1246/bcsj.56.2762

  日期：1983.9

  of 4-substituted 2-acylphenoxyacetic acids give a mixture of benzofurans and 2-benzofurancarboxylic acids. The relative yields of benzofurans and 2-benzofurancarboxylic acids depend on the substituents on the benzene ring of the 2-acylphenoxyacetic acids. Electron-withdrawing substituents such as nitro groups favor the formation of 2-benzofurancarboxylic acids. On the other hand, the formation of benzofurans

  4-取代的2-酰基苯氧基乙酸的Rossing反应得到苯并呋喃和2-苯并呋喃甲酸的混合物。苯并呋喃和 2-苯并呋喃甲酸的相对产率取决于 2-酰基苯氧乙酸苯环上的取代基。吸电子取代基如硝基有利于形成 2-苯并呋喃甲酸。另一方面，在 2-酰基-4-硝基苯氧乙酸与无水乙酸钠和乙酸酐的反应中，2-酰基的空间位阻有利于苯并呋喃的形成。
• Lead optimization of a pyridine-carboxamide series as DGAT-1 inhibitors
  作者：Pauline C. Ting、Joe F. Lee、Nicolas Zorn、Hyunjin M. Kim、Robert G. Aslanian、Mingxiang Lin、Michelle Smith、Scott S. Walker、John Cook、Margaret Van Heek、Jean Lachowicz

  DOI：10.1016/j.bmcl.2012.12.040

  日期：2013.2

  The structure–activity relationship studies of a novel series of carboxylic acid derivatives of pyridine-carboxamides as DGAT-1 inhibitors is described. The optimization of the initial lead compound 6 based on in vitro and in vivo activity led to the discovery of key compounds 10j and 17h.

  描述了一系列新型的吡啶甲酰胺类羧酸衍生物作为DGAT-1抑制剂的构效关系。基于体外和体内活性的初始铅化合物6的优化导致关键化合物10j和17h的发现。
• [EN] PROTEASE INHIBITORS<br/>[FR] INHIBITEURS DE PROTEASES
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2001095911A1

  公开（公告）日：2001-12-20

  The present invention provides 4-amino-azepan-3-one protease inhibitors and pharmaceutically acceptable salts, hydrates and solvates thereof which inhibit proteases, including cathepsin K, pharmaceutical compositions of such compounds, novel intermediates of such compounds, and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis; gingival disease including gingivitis and periodontitis; arthritis, more specifically, osteoarthritis and rheumatoid arthritis; Paget's disease; hypercalcemia of malignancy; and metabolic bone disease, comprising inhibiting said bone loss or excessive cartilage or matrix degradation by administering to a patient in need thereof a compound of the present invention.

  本发明提供了4-氨基-氮杂七环-3-酮蛋白酶抑制剂及其药学上可接受的盐、水合物和溶剂化物，该抑制剂可以抑制蛋白酶，包括卡他蛋白K，以及这些化合物的药物组合物、这些化合物的新中间体，以及治疗骨量过度流失、软骨或基质降解等疾病的方法，包括骨质疏松症；牙龈疾病，包括牙龈炎和牙周炎；关节炎，更具体地说是骨关节炎和类风湿性关节炎；帕吉特病；恶性高钙血症；以及代谢性骨病，通过向需要治疗的患者施用本发明的化合物来抑制骨量过度流失或过度软骨或基质降解。
• Method of treatment
  申请人：SmithKline Beecham Corporation

  公开号：US20030044399A1

  公开（公告）日：2003-03-06

  The present invention relates to methods of treating parasitic diseases which are mediated by cysteine proteases by administration of 4-amino-azepan-3-one protease inhibitors. In particular, the present invention relates to a method of treating malaria by inhibiting the cysteine protease falcipain.

  本发明涉及通过给予4-氨基-氮杂辛酮蛋白酶抑制剂治疗由半胱氨酸蛋白酶介导的寄生病的方法。特别地，本发明涉及通过抑制半胱氨酸蛋白酶falcipain来治疗疟疾的方法。